Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

This trial tests a new drug called LP-284 in people with relapsed or treatment-resistant lymphomas (B-cell non-Hodgkin lymphoma, mantle cell lymphoma) and advanced solid tumors. The drug is designed to target a specific pattern in cancer cell DNA that makes some cancers more vulnerable to it. **You may be eligible if...** - You are 18 or older with relapsed or refractory B-cell lymphoma or mantle cell lymphoma that has come back after at least 2 prior treatments - Or you have an advanced solid tumor with no remaining standard treatment options - You are in reasonably good health (ECOG performance status 0-2) - Your blood counts, liver, and kidney function are adequate **You may NOT be eligible if...** - You have had a stem cell transplant from a donor - You have active CNS (brain) lymphoma involvement - You have had a blood clot or stroke within the past 6 months - You have active hepatitis B, hepatitis C, or HIV infection - You are pregnant or breastfeeding - You have had radiation or major surgery within the past 4 weeks Talk to your doctor to see if this trial is right for you.